Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
Chen B, Francis A, Cooper SA, Dobson R, Hacohen Y, Halfpenny C, Hemingway C, Hobart JC, O'Sullivan E, Rashid W, Martin RJ, Williams V, Ramdas S, Geraldes R, Leite MIS, Palace J. Chen B, et al. Among authors: hobart jc. Neurology. 2025 Jan 14;104(1):e210137. doi: 10.1212/WNL.0000000000210137. Epub 2024 Dec 12. Neurology. 2025. PMID: 39666920
Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?
Chen B, Gomez-Figueroa E, Redenbaugh V, Francis A, Satukijchai C, Wu Y, Messina S, Sa M, Woodhall M, Paul F, Robertson NP, Lim M, Wassmer E, Kneen R, Huda S, Blain C, Halfpenny C, Hemingway C, O'Sullivan E, Hobart J, Fisniku LK, Martin RJ, Dobson R, Cooper SA, Williams V, Waters P, Chen JJ, Pittock SJ, Ramdas S, Leite MI, Flanagan EP, Geraldes R, Palace J. Chen B, et al. Ann Neurol. 2023 Sep;94(3):508-517. doi: 10.1002/ana.26731. Epub 2023 Jul 12. Ann Neurol. 2023. PMID: 37394961
Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom.
Satukijchai C, Mariano R, Messina S, Sa M, Woodhall MR, Robertson NP, Ming L, Wassmer E, Kneen R, Huda S, Jacob A, Blain C, Halfpenny C, Hemingway C, O'Sullivan E, Hobart J, Fisniku LK, Martin R, Dopson R, Cooper SA, Williams V, Waters PJ, Ramdas S, Leite MI, Palace J. Satukijchai C, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2142780. doi: 10.1001/jamanetworkopen.2021.42780. JAMA Netw Open. 2022. PMID: 35006246 Free PMC article.
Modafinil for multiple sclerosis fatigue: does it work?
Littleton ET, Hobart JC, Palace J. Littleton ET, et al. Among authors: hobart jc. Clin Neurol Neurosurg. 2010 Jan;112(1):29-31. doi: 10.1016/j.clineuro.2009.09.004. Epub 2009 Oct 17. Clin Neurol Neurosurg. 2010. PMID: 19837509
Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre, observational study of multiple sclerosis diagnostic pathways in the United Kingdom and Republic of Ireland.
Kuri A, Henshall DE, Chaudhry D, Ooi SZY, Zhang Q, Mathews J, Thomson A, Rog D, Hobart J, Dobson R; Neurology and Neurosurgery Interest Group (NANSIG). Kuri A, et al. BMC Neurol. 2024 Mar 28;24(1):105. doi: 10.1186/s12883-024-03598-z. BMC Neurol. 2024. PMID: 38539132 Free PMC article.
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S; MS-SMART Investigators. Chataway J, et al. Lancet Neurol. 2020 Mar;19(3):214-225. doi: 10.1016/S1474-4422(19)30485-5. Epub 2020 Jan 22. Lancet Neurol. 2020. PMID: 31981516 Free PMC article. Clinical Trial.
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis.
Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S, Hemingway C, Hobart J, Evangelou N, Scolding N, Rog D, Nicholas R, Marta M, Blain C, Young CA, Ford HL, Matthews PM. Dobson R, et al. BMJ Open. 2021 Nov 25;11(11):e050176. doi: 10.1136/bmjopen-2021-050176. BMJ Open. 2021. PMID: 34824113 Free PMC article.
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
Blackstone J, Williams T, Nicholas JM, Bordea E, De Angelis F, Bianchi A, Calvi A, Doshi A, John N, Apap Mangion S, Wade C, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson N, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri S, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Nixon SJ, Beveridge J, Hawton A, Tebbs S, Braisher M, Giovannoni G, Ciccarelli O, Greenwood J, Thompson AJ, Hunter R, Pavitt S, Pearson O, Evangelou N, Sharrack B, Galea I, Chandran S, Ford HL, Frost C, Chataway J. Blackstone J, et al. BMJ Open. 2024 Sep 16;14(9):e086414. doi: 10.1136/bmjopen-2024-086414. BMJ Open. 2024. PMID: 39284697 Free PMC article. Clinical Trial.
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.
Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC, Chowdhury F, Stutters J, Ricciardi A, Prados F, MacManus D, Braisher M, Blackstone J, Ciccarelli O, Gandini Wheeler-Kingshott CAM, Barkhof F, Chataway J; UCL MS-STAT2 investigators. Williams T, et al. Eur J Neurol. 2023 Sep;30(9):2769-2780. doi: 10.1111/ene.15924. Epub 2023 Jun 23. Eur J Neurol. 2023. PMID: 37318885 Clinical Trial.
101 results